64 studies found for:    cabozantinib
Show Display Options
Rank Status Study
1 Recruiting Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions: NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention: Drug: Cabozantinib
2 Recruiting Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Panitumumab;   Drug: Cabozantinib
3 Recruiting Cabozantinib for Malignant Pheochromocytoma
Condition: Neuroendocrine Tumors
Interventions: Drug: Cabozantinib;   Behavioral: Questionnaire
4 Recruiting A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Condition: Prostate Cancer
Intervention: Drug: Cabozantinib
5 Active, not recruiting A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Conditions: Bile Duct Cancer;   Intrahepatic Cholangiocarcinoma;   Cholangiocarcinoma of the Extrahepatic Bile Duct
Intervention: Drug: Cabozantinib
6 Active, not recruiting Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Conditions: Childhood Solid Neoplasm;   Recurrent Melanoma;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
7 Active, not recruiting Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
8 Active, not recruiting Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Conditions: Solid Tumors;   Cancer;   NSCLC
Interventions: Drug: cabozantinib capsules;   Drug: cabozantinib tablets
9 Recruiting Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
Conditions: Adult Solid Neoplasm;   HIV Infection
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
10 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib tablets;   Drug: Placebo tablets
11 Recruiting Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Conditions: Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage I Thyroid Gland Follicular Carcinoma;   Stage I Thyroid Gland Papillary Carcinoma;   Stage II Thyroid Gland Follicular Carcinoma;   Stage II Thyroid Gland Papillary Carcinoma;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
12 Recruiting Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Cabozantinib;   Drug: Androgen Ablation Therapy
13 Active, not recruiting Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Cabozantinib S-malate;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
14 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
15 Suspended Cabozantinib in Advanced Solid Malignancies
Conditions: Lung Cancer;   Solid Tumor (Not Breast or Prostate Cancers)
Intervention: Drug: Cabozantinib
16 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Conditions: Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
17 Recruiting Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
18 Terminated Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Drug: vemurafenib;   Other: laboratory biomarker analysis;   Other: pharmacological study
19 Suspended Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Ocular Melanoma With Extraocular Extension;   Recurrent Uveal Melanoma;   Small Size Posterior Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Dacarbazine;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
20 Active, not recruiting Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years